(Reuters) -AstraZeneca said on Friday its Alexion unit had agreed to buy U.S. drugmaker Pfizer's early-stage rare disease gene therapy portfolio for up to $1 billion, plus royalties on sales, as the ...
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Alexion, AstraZeneca Rare Disease, will showcase 14 studies, including real-world evidence (RWE), from their portfolio and pipeline of ...
Monopar Therapeutics, Inc. (NASDAQ:MNPR) shares are trading lower Friday after gaining on Thursday. The stock was volatile yesterday following the company’s agreement with Alexion, AstraZeneca Rare ...
AstraZeneca Plc. AZN said its Phase 3 I CAN trial evaluating Ultomiris (ravulizumab) in adults with immunoglobulin A ...
A year after nabbing FDA approval for its rare disease drug Ultomiris in generalized myasthenia gravis (gMG), AstraZeneca has launched the first TV ad for the therapy. For AstraZeneca, this ad is a ...
An AstraZeneca drug acquired in a $930 million deal has received FDA approval as a treatment for a rare blood disorder. In this disease, paroxysmal nocturnal hemoglobinuria (PNH), a part of the immune ...
A year after debuting the “Rare Connections” series with a short film about patients’ experiences with neuromyelitis optica spectrum disorder (NMOSD), AstraZeneca’s rare disease unit is turning the ...
Pangaea Data, a company focused on detecting hard-to-diagnose diseases in patients, is partnering with Alexion, a subsidiary of AstraZeneca focused on treating rare diseases, to co-develop, clinically ...
(RTTNews) - Wednesday, Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, has entered into a Letter of Intent with the pan-Canadian Pharmaceutical Alliance for Koselugo for the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results